{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:21:09Z","timestamp":1793931669356,"version":"4.8.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019720","name":"GlaxoSmithKline Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019720","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Blood eosinophil count is usually employed as a predictive and response biomarker for mepolizumab treatment. However, its decrease is not always associated with an improvement in asthma symptoms. The aim of this work is to study the effect of mepolizumab in the activation status and functional phenotype of circulating eosinophils.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Samples from healthy controls (N = 15) and patients with severe eosinophilic asthma (N = 15) before and after 4, 16 and 32 weeks of mepolizumab treatment (anti-IL5 mAb; 100 mg s.c.\/4 weeks) were screened. Demographic, clinical, hematological and biochemical characteristics were collected. Activation and functional phenotype of peripheral blood eosinophils was analyzed by flow cytometry. sCD62L in serum was measured by ELISA. Target mRNAs were quantified by Nanostring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eosinophils from severe eosinophilic asthma patients showed a higher activation profile (CD11b, CD44 and IL-5R\u03b1 expression) compared to healthy subjects. Mepolizumab treatment reduced the number of basophils and eosinophils in peripheral blood. We also found a clear downmodulation on the surface expression (% and MFI) of CD44 and IL-3R\u03b1 on eosinophils at week 4, which was maintained through all treatment period (4\u201332 weeks). The functional phenotype of the remaining eosinophils was also modified with the treatment, showing a reduction of inflammatory eosinophils (iEOS; CD62L\n                      <jats:sup>lo<\/jats:sup>\n                      ) percentage without affecting the balance of regulatory subpopulations (CD16\n                      <jats:sup>dim\/hi<\/jats:sup>\n                      eosinophils). This was accompanied by a decrease in serum sCD62L levels. mRNA and protein levels showed similar trends for some targets (e.g., IL-5R\u03b1) but not for others (e.g., CD62L).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Mepolizumab treatment modifies the functional phenotype of eosinophils resulting in a lower percentage of iEOS and reduced activation status. These changes occur at an early time point (4 weeks) and are maintained throughout all treatment period.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1654111","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T05:13:12Z","timestamp":1764220392000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Mepolizumab treatment alters the functional phenotype of eosinophils in severe eosinophilic asthma"],"prefix":"10.3389","volume":"16","author":[{"given":"Pablo","family":"Migu\u00e9ns-Su\u00e1rez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Martelo-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"V\u00e1zquez-Mera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Blanco-Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ux\u00edo","family":"Calvo-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coral","family":"Gonz\u00e1lez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Mosteiro-A\u00f1\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Corbacho-Abelaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Hermida-Valverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Calvo-Henr\u00edquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J.","family":"Nieto-Fontarigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Gonz\u00e1lez-Barcala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2024.01.023","article-title":"Phenotyping of severe asthma in the era of broad-acting anti-asthma biologics","volume":"12","author":"Bourdin","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.04.013","article-title":"Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort","volume":"160","author":"Heaney","year":"2021","journal-title":"Chest"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200906-0896OC","article-title":"Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program","volume":"181","author":"Moore","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00779-2015","article-title":"Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort","volume":"46","author":"Shaw","year":"2015","journal-title":"Eur Respir J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00100-2015","article-title":"Clinical profile of patients with adult-onset eosinophilic asthma","volume":"2","author":"de Groot","year":"2016","journal-title":"ERJ Open Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8091375","article-title":"Severe eosinophilic asthma","volume":"8","author":"Bakakos","year":"2019","journal-title":"J Clin Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.01514","article-title":"Interleukin-5 in the pathophysiology of severe asthma","volume":"10","author":"Pelaia","year":"2019","journal-title":"Front Physiol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet Lond Engl"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2000151","DOI":"10.1183\/13993003.00151-2020","article-title":"Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis","volume":"56","author":"Harrison","year":"2020","journal-title":"Eur Respir J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106595","article-title":"Efficacy of mepolizumab in usual clinical practice and characteristics of responders","volume":"187","author":"Rodr\u00edguez-Garc\u00eda","year":"2021","journal-title":"Respir Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0905","article-title":"REDES study: mepolizumab is effective in patients with severe asthma and comorbid nasal polyps","volume":"33","author":"Arismendi","year":"2023","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.04.014","article-title":"Low blood eosinophil counts are not always a reliable marker of clinical response to mepolizumab in severe asthma","volume":"6","author":"Ojanguren","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12292","article-title":"Activation states of blood eosinophils in asthma","volume":"44","author":"Johansson","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10092181","article-title":"Eosinophilic inflammation: an appealing target for pharmacologic treatments in severe asthma","volume":"10","author":"Vatrella","year":"2022","journal-title":"Biomedicines"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601005","article-title":"Regulatory eosinophils suppress T cells partly through galectin-10","volume":"198","author":"Lingblom","year":"2017","journal-title":"J Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85664","article-title":"Lung-resident eosinophils represent a distinct regulatory eosinophil subset","volume":"126","author":"Mesnil","year":"2016","journal-title":"J Clin Invest"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/all.15751","article-title":"Eosinophils from A to Z","volume":"78","author":"Gigon","year":"2023","journal-title":"Allergy"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.12.8053","article-title":"Expression and regulation of the metalloproteinase ADAM-8 during human neutrophil pathophysiological activation and its catalytic activity on L-selectin shedding","volume":"178","author":"G\u00f3mez-Gaviro","year":"2007","journal-title":"J Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2020.101946","article-title":"Effectiveness of mepolizumab therapy in patients with severe eosinophilic asthma: Austrian real-life data","volume":"64","author":"Renner","year":"2020","journal-title":"Pulm Pharmacol Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11092424","article-title":"Long-term efficacy of mepolizumab at 3 years in patients with severe asthma: comparison with clinical trials and super responders","volume":"11","author":"Bagnasco","year":"2023","journal-title":"Biomedicines"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1902345","DOI":"10.1183\/13993003.02345-2019","article-title":"Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme","volume":"55","author":"Taill\u00e9","year":"2020","journal-title":"Eur Respir J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201611-2234OC","article-title":"Mepolizumab attenuates airway eosinophil numbers, but not their functional phenotype, in asthma","volume":"196","author":"Kelly","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.mucimm.2024.03.005","article-title":"IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthma","volume":"17","author":"Luo","year":"2024","journal-title":"Mucosal Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1183\/09031936.03.00027302","article-title":"Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions","volume":"21","author":"B\u00fcttner","year":"2003","journal-title":"Eur Respir J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.jaci.2008.02.033","article-title":"Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels","volume":"121","author":"Stein","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102913","article-title":"Differential effects of short- and long-term treatment with mepolizumab on eosinophil kinetics in blood and sputum in eosinophilic asthma","volume":"24","author":"Hassani","year":"2021","journal-title":"iScience"},{"key":"B30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S0006-291X(03)01526-2","article-title":"Changing expression of IL-3 and IL-5 receptors in cultured human eosinophils","volume":"309","author":"Yoshimura-Uchiyama","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2009.03325.x","article-title":"Haemopoietic processes in allergic disease: eosinophil\/basophil development","volume":"39","author":"Gauvreau","year":"2009","journal-title":"Clin Exp Allergy J Br Soc Allergy Clin Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12876","article-title":"IL-3 up-regulates and activates human eosinophil CD32 and \u03b1M\u03b22 integrin causing degranulation","volume":"47","author":"Esnault","year":"2017","journal-title":"Clin Exp Allergy J Br Soc Allergy Clin Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.22174","article-title":"Flow cytometric immunophenotypic differentiation patterns of bone marrow eosinophilopoiesis","volume":"106","author":"Trindade","year":"2024","journal-title":"Cytometry B Clin Cytom"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2018.03.006","article-title":"Expression of Siglec-8 is regulated by interleukin-5, and serum levels of soluble Siglec-8 may predict responsiveness of severe eosinophilic asthma to mepolizumab","author":"Arakawa","year":"2018","journal-title":"Allergol Int"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2009-0168OC","article-title":"Thymic stromal lymphopoietin induces chemotactic and prosurvival effects in eosinophils: implications in allergic inflammation","volume":"43","author":"Wong","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb\/8.6.633","article-title":"Selective regulation of expression of surface adhesion molecules Mac-1, L-selectin, and VLA-4 on human eosinophils and neutrophils","volume":"8","author":"Neeley","year":"1993","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1159\/000053590","article-title":"Interferon-gamma increases CD62L expression on human eosinophils","volume":"120","author":"Momose","year":"1999","journal-title":"Int Arch Allergy Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043469","article-title":"Blood inflammatory-like and lung resident-like eosinophils affect migration of airway smooth muscle cells and their ECM-related proliferation in asthma","volume":"24","author":"Rimkunas","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11090829","article-title":"\u03b14\u03b21 and \u03b1M\u03b22 integrin expression and pro-proliferative properties of eosinophil subtypes in asthma","volume":"11","author":"Jurkeviciute","year":"2021","journal-title":"J Pers Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/cells11233804","article-title":"IL-5 and GM-CSF, but not IL-3, promote the proliferative properties of inflammatory-like and lung resident-like eosinophils in the blood of asthma patients","volume":"11","author":"Palacionyte","year":"2022","journal-title":"Cells"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051248","article-title":"Blood eosinophils subtypes and their survivability in asthma patients","volume":"9","author":"Januskevicius","year":"2020","journal-title":"Cells"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/all.15670","article-title":"C5aR1 activation in mice controls inflammatory eosinophil recruitment and functions in allergic asthma","volume":"78","author":"Wiese","year":"2023","journal-title":"Allergy"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202301-0149OC","article-title":"Eosinophil subtypes in adults with asthma and adults with chronic obstructive pulmonary disease","volume":"208","author":"Cabrera L\u00f3pez","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/cea.14153","article-title":"High proportion of inflammatory CD62Llow eosinophils in blood and nasal polyps of severe asthma patients","volume":"53","author":"Matucci","year":"2023","journal-title":"Clin Exp Allergy J Br Soc Allergy Clin Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/all.15909","article-title":"Blood CD62Llow inflammatory eosinophils are related to the severity of asthma and reduced by mepolizumab","volume":"78","author":"Vultaggio","year":"2023","journal-title":"Allergy"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/all.16267","article-title":"Mepolizumab depletes inflammatory but preserves homeostatic eosinophils in severe asthma","volume":"79","author":"Fricker","year":"2024","journal-title":"Allergy"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2100935","DOI":"10.1183\/13993003.00935-2021","article-title":"Anti-IL5 mepolizumab minimally influences residual blood eosinophils in severe asthma","volume":"59","author":"Van Hulst","year":"2022","journal-title":"Eur Respir J"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1159\/000508936","article-title":"Personalized approach of severe eosinophilic asthma patients treated with mepolizumab and benralizumab","volume":"181","author":"Bergantini","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jaci.2024.01.031","article-title":"Activated sputum eosinophils associated with exacerbations in children on mepolizumab","volume":"154","author":"Wilson","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.121952","article-title":"Expression of Fc\u03b3RIII (CD16) on human peripheral blood eosinophils increases in allergic conditions","volume":"109","author":"Davoine","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13540","article-title":"Kinetic studies of galectin-10 release from eosinophils exposed to proliferating T cells","volume":"203","author":"Lingblom","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.5415\/apallergy.2021.11.e31","article-title":"Mepolizumab decreased the levels of serum galectin-10 and eosinophil cationic protein in asthma","volume":"11","author":"Kobayashi","year":"2021","journal-title":"Asia Pac Allergy"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2017.00068","article-title":"Regulation of eosinophil recruitment and activation by galectins in allergic asthma","volume":"4","author":"Rao","year":"2017","journal-title":"Front Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1654111\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T05:13:13Z","timestamp":1764220393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1654111\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":53,"alternative-id":["10.3389\/fimmu.2025.1654111"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1654111","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"article-number":"1654111"}}